Amylyx Pharmaceuticals is a company engaged in the development of therapies for neurodegenerative and endocrine disorders. It develops drug candidates including avexitide, AMX0035, AMX0114, and AMX0318 for post-bariatric hypoglycemia, congenital hyperinsulinism, Wolfram syndrome, and amyotrophic lateral sclerosis. The company operates in the neurodegenerative and endocrine disorder markets.